Literature DB >> 7824878

Etiology and pathogenesis in primary sclerosing cholangitis.

K M Boberg1, K E Lundin, E Schrumpf.   

Abstract

The etiology and pathogenesis of the inflammatory and fibrotic bile duct lesions characteristic of primary sclerosing cholangitis (PSC) is unknown, but several lines of evidence support the contention that genetic and immunologic factors are involved. There is an association with human leukocyte antigens (HLA) with an increased frequency of DR3, DR6, and DR2 positive haplotypes. DRB3*0101(DR52a) is the most strongly associated allele in some studies, but the HLA gene conferring the primary HLA associated susceptibility to PSC remains to be established. There is an aberrant expression of HLA class II antigens (DR and DP) on bile duct epithelial cells, with the potential to present antigens to the surrounding T-lymphocytes. A defective suppressor T-cell function has been suggested in some studies. The patients may have elevated levels of circulating immune complexes, immunoglobulins, and non-organ-specific autoantibodies. Antibodies to perinuclear antigens (pANCA) are present in about 80% of cases. Increased metabolism of complement C3, reduced clearance of immune complexes, and increased concentration of biliary immune complexes have been found. The strong association between PSC and ulcerative colitis (UC) has not been explained. The detection of circulating IgG antibodies against a specific epitope shared by epithelial cells in the bile ducts and colon in about two-thirds of PSC patients may be of importance. Portal bacteremia secondary to a diseased bowel may possibly contribute to development of liver disease in UC. Viral infections and toxic and ischemic factors have also been implicated in the pathogenesis of PSC. In conclusion, PSC seems to occur in genetically predisposed individuals, mediated by immunologic mechanisms. The primary event triggering the disease development is, however, unknown.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824878     DOI: 10.3109/00365529409103625

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  5 in total

1.  Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis.

Authors:  Yoshihiro Numata; Susuma Tazuma; Yoshitaka Ueno; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.

Authors:  X Bo; U Broome; M Remberger; S Sumitran-Holgersson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.

Authors:  B Xu; U Broome; B-G Ericzon; S Sumitran-Holgersson
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

4.  Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis.

Authors:  T Orth; R Kellner; O Diekmann; J Faust; K H Meyer zum Büschenfelde; W J Mayet
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis.

Authors:  Randeep Kashyap; Parvez Mantry; Rajeev Sharma; Manoj K Maloo; Saman Safadjou; Yanjie Qi; Ashok Jain; Benedict Maliakkal; Charlotte Ryan; Mark Orloff
Journal:  J Gastrointest Surg       Date:  2009-05-09       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.